tadalafil has been researched along with beraprost in 5 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (beraprost) | Trials (beraprost) | Recent Studies (post-2010) (beraprost) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 407 | 61 | 105 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aizawa, T; Hatano, M; Inaba, T; Kinugawa, K; Maki, H; Nagai, R; Shiga, T; Yamashita, T; Yao, A | 1 |
| Watanabe, H | 1 |
| Fujita, J; Fukuda, K; Kataoka, M; Kimura, M; Kuwana, M; Ono, T; Satoh, T; Takei, M; Tamura, Y; Yamamoto, T | 1 |
| Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Ko, T; Komuro, I; Maki, H; Minatsuki, S; Muraoka, H; Nitta, D; Yao, A | 1 |
| Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
1 review(s) available for tadalafil and beraprost
| Article | Year |
|---|---|
[Pharmacological treatment of pulmonary hypertension at a turning point].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Carbolines; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vascular Resistance; Vasodilator Agents | 2014 |
4 other study(ies) available for tadalafil and beraprost
| Article | Year |
|---|---|
Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Carbolines; Cardiac Output; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Echocardiography; Electrocardiography; Epoprostenol; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Middle Aged; Sulfonamides; Tadalafil; Vasodilator Agents | 2011 |
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pilot Projects; Prostaglandins; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance; Young Adult | 2015 |
A case of interferon-α-induced pulmonary arterial hypertension after living donor liver transplantation.
Topics: Antihypertensive Agents; Arterial Pressure; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Immunologic Factors; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Pulmonary Artery; Tadalafil; Treatment Outcome | 2016 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |